Search results
Found 39 matches for
NEOPANC-01 is a window of opportunity study looking to assess gene expression in patients with resectable pancreatic cancer. It aims to evaluate the utility of whole transcriptome RNA sequencing as a potential biomarker for future window-of-opportunity trials that will assess existing and/or new treatments for pancreatic cancer. An understanding of the variability in the transcriptomic signature between biopsies will also inform power calculations for future studies. Lastly, the data generated will be available for use as historical controls for future studies. 2 sets of biopsy samples will be taken throughout the trial. Firstly during an endoscopic ultrasound procedure and then again, up to 6 weeks later, during the patients surgery to remove the cancer. Once all patients have been recruited, the mRNA from the samples will be sequenced and analysed. Further samples will also be taken at the same time points for storage into a biobank and for use in future research. This is a single site study opening at the Churchill Hospital looking to recruit 10 patients over 18 months.
Health Economics & Outcomes Research
Arthritis Botnar Orthopaedics and trauma Statistics and epidemiology
Our research aims to improve people's health and wellbeing by making the most efficient use of health and social care resources. To achieve this, we use real-world data and mathematical models to evaluate the costs and consequences of applying different interventions over a period of time, often the entire lifetime of patients.
Dakin Group | Soft Tissue Joint Disease
Botnar Inflammation biology Orthopaedics and trauma Tissue remodelling and regeneration
The Dakin Group undertakes translational research focusing on identifying the cellular and molecular basis of inflammatory fibrotic soft tissue joint diseases, with research programmes on tendinopathy, frozen shoulder and knee arthrofibrosis. Understanding the cellular and molecular basis of these diseases will inform new therapeutic approaches targeting tissue resident stromal cells of the joint, to promote resolution of inflammatory fibrotic disease.